Research programme: small molecule therapeutics - Curadev Pharma

Drug Profile

Research programme: small molecule therapeutics - Curadev Pharma

Alternative Names: CRD 1400

Latest Information Update: 26 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Curadev Pharma
  • Developer Curadev Pharma; Roche; University of Texas Southwestern Medical Center
  • Class Anti-inflammatories; Antineoplastics; Small molecules
  • Mechanism of Action Acetate-CoA ligase inhibitors; Coenzyme-A ligase inhibitors; Indoleamine-pyrrole 2,3-dioxygenase inhibitors; Phosphotransferase inhibitors; Transcription factor modulators; Tryptophan oxygenase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Breast cancer; Cancer; Haematological malignancies; Solid tumours
  • Research Glioblastoma; Immunological disorders; Malignant melanoma

Most Recent Events

  • 21 Apr 2018 Preclinical trials in Cancer in India (unspecified route)
  • 07 Dec 2017 Curadev Pharma and University of Texas Southwestern Medical Center agree to co-develop small molecule therapeutics for cancer
  • 07 Dec 2017 Early research in Glioblastoma in USA, India
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top